Jazz Pharmaceuticals plc (JAZZ)
NASDAQ$137.96
Market Cap
$8.38B
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
662 of 924
Rank in Industry
376 of 527
Insider Buys Sum
Cluster
Trading
Trading
Insider Buys
Quantity
Quantity
Historical
Profitability
Profitability
Investor
Ownership
Ownership
Largest Insider Buys in Sector
JAZZ Insider Trading Activity
JAZZ Median Price and Trade Amounts History Chart
Statistics of Insider Transactions
Amount of Insider Buys and Sells
Buys | $0 | 0 | 0 |
Sells | $5,018,696 | 16 | 100 |
Related Transactions
| Henderson Mary Elizabeth | SVP, Technical Operations | 0 | $0 | 1 | $152,703 | $-152,703 |
| Carr Patricia | SVP, Chief Accounting Officer | 0 | $0 | 5 | $337,303 | $-337,303 |
| Iannone Robert | EVP, Global Head of R&D & CMO | 0 | $0 | 2 | $1.31M | $-1.31M |
| Patil Neena M | EVP & Chief Legal Officer | 0 | $0 | 3 | $1.56M | $-1.56M |
| COZADD BRUCE C | Chairman & CEO | 0 | $0 | 5 | $1.66M | $-1.66M |
About Jazz Pharmaceuticals plc
Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of neuroscience, including sleep medicine and movement disorders; and in oncology, including hematologic and solid tumors. Its lead marketed products include Xyrem, an oral solution for the treatment of cataplexy and excessive daytime sleepiness (EDS) in …
Insider Activity of Jazz Pharmaceuticals plc
Over the last 12 months, insiders at Jazz Pharmaceuticals plc have bought $0 and sold $5.02M worth of Jazz Pharmaceuticals plc stock.
On average, over the past 5 years, insiders at Jazz Pharmaceuticals plc have bought $3.49M and sold $10.5M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 12,000 shares for transaction amount of $1.44M was made by Johnson Philip L (EVP & Chief Financial Officer) on 2024‑03‑01.
List of Insider Buy and Sell Transactions, Jazz Pharmaceuticals plc
| 2025-03-10 | Sale | Iannone Robert | EVP, Global Head of R&D & CMO | 2,403 0.004% | $138.41 | $332,605 | -0.72% | |
| 2025-03-10 | Sale | Carr Patricia | SVP, Chief Accounting Officer | 1,140 0.0019% | $137.81 | $157,103 | -0.72% | |
| 2025-03-07 | Sale | Iannone Robert | EVP, Global Head of R&D & CMO | 7,080 0.0116% | $138.60 | $981,298 | -1.40% | |
| 2025-03-03 | Sale | COZADD BRUCE C | Chairman & CEO | 6,500 0.011% | $144.25 | $937,625 | -1.98% | |
| 2025-02-28 | Sale | Carr Patricia | SVP, Chief Accounting Officer | 773 0.0013% | $143.29 | $110,767 | -4.03% | |
| 2025-02-27 | Sale | Patil Neena M | EVP & Chief Legal Officer | 3,800 0.0064% | $144.87 | $550,506 | -3.71% | |
| 2025-02-27 | Sale | Carr Patricia | SVP, Chief Accounting Officer | 313 0.0005% | $144.42 | $45,202 | -3.71% | |
| 2025-02-03 | Sale | COZADD BRUCE C | Chairman & CEO | 1,500 0.0024% | $122.31 | $183,465 | +12.12% | |
| 2025-01-02 | Sale | COZADD BRUCE C | Chairman & CEO | 1,500 0.0025% | $123.43 | $185,145 | +0.78% | |
| 2024-12-02 | Sale | COZADD BRUCE C | Chairman & CEO | 2,000 0.0033% | $121.17 | $242,340 | +1.60% | |
| 2024-12-02 | Sale | Carr Patricia | SVP, Chief Accounting Officer | 53 <0.0001% | $122.49 | $6,492 | +1.60% | |
| 2024-11-08 | Sale | Patil Neena M | EVP & Chief Legal Officer | 3,700 0.006% | $123.41 | $456,617 | -0.07% | |
| 2024-11-01 | Sale | COZADD BRUCE C | Chairman & CEO | 1,000 0.0016% | $110.84 | $110,840 | +11.77% | |
| 2024-09-06 | Sale | Henderson Mary Elizabeth | SVP, Technical Operations | 1,410 0.0023% | $108.30 | $152,703 | +13.63% | |
| 2024-06-07 | Sale | Carr Patricia | SVP, Chief Accounting Officer | 163 0.0003% | $108.83 | $17,738 | +2.23% | |
| 2024-05-03 | Sale | Patil Neena M | EVP & Chief Legal Officer | 5,000 0.008% | $109.65 | $548,250 | +2.81% | |
| 2024-03-07 | Sale | Carr Patricia | SVP, Chief Accounting Officer | 1,768 0.0028% | $116.98 | $206,821 | -2.79% | |
| 2024-03-06 | Sale | Carr Patricia | SVP, Chief Accounting Officer | 1,936 0.0032% | $119.64 | $231,628 | -3.47% | |
| 2024-03-01 | Johnson Philip L | EVP & Chief Financial Officer | 12,000 0.0192% | $119.65 | $1.44M | -4.82% | ||
| 2023-12-04 | Sale | Smith Mark Douglas | director | 417 0.0007% | $119.27 | $49,736 | -6.84% |
Total: 569
*Gray background shows transactions not older than one year
Insider Historical Profitability
<0.0001%
| COZADD BRUCE C | Chairman & CEO | 464058 0.7641% | $64.02M | 1 | 105 | +194.39% |
| MICHELSON MICHAEL W | director | 9906501 16.3117% | $1.37B | 1 | 0 | <0.0001% |
| RAETHER PAUL E | 9906501 16.3117% | $1.37B | 1 | 0 | <0.0001% | |
| KKR JP LLC | 9906501 16.3117% | $1.37B | 1 | 0 | <0.0001% | |
| BRIDGER MANAGEMENT LLC | 10 percent owner | 2667050 4.3915% | $367.95M | 9 | 0 | <0.0001% |
*Gray background shows insiders who have made transactions during last year
Historical Insider Profitability vs. Competitors
$961,890,236 | 276 | 22.46% | $13.13B | |
$159,914,414 | 243 | 18.52% | $5.91B | |
$211,610,344 | 91 | 38.45% | $7.69B | |
$2,765,836 | 72 | 20.00% | $13.25B | |
$108,876,545 | 67 | 72.81% | $7.67B |
JAZZ Institutional Investors: Active Positions
| Increased Positions | 256 | +47.32% | 6M | +10.27% |
| Decreased Positions | 231 | -42.7% | 5M | -8.18% |
| New Positions | 88 | New | 2M | New |
| Sold Out Positions | 57 | Sold Out | 924,727 | Sold Out |
| Total Postitions | 566 | +4.62% | 59M | +2.09% |
JAZZ Ownership Change vs Market
Institutional Investor Ownership
Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
| Vanguard Group Inc | $866,373.00 | 9.9% | 6.04M | -71,326 | -1.17% | 2024-12-31 |
| Blackrock, Inc. | $839,826.00 | 9.59% | 5.85M | -21,409 | -0.36% | 2024-12-31 |
| Lsv Asset Management | $363,282.00 | 4.15% | 2.53M | +37,108 | +1.49% | 2024-12-31 |
| Pacer Advisors, Inc. | $317,844.00 | 3.63% | 2.21M | +115,102 | +5.48% | 2024-12-31 |
| Dimensional Fund Advisors Lp | $292,094.00 | 3.34% | 2.04M | +320,724 | +18.71% | 2024-12-31 |
| State Street Corp | $282,585.00 | 3.23% | 1.97M | +22,549 | +1.16% | 2024-12-31 |
| Capital World Investors | $276,057.00 | 3.15% | 1.92M | +104,195 | +5.73% | 2024-12-31 |
| Ameriprise Financial Inc | $262,324.00 | 3% | 1.83M | +315,608 | +20.87% | 2024-12-31 |
| Ecor1 Capital, Llc | $244,929.00 | 2.8% | 1.71M | 0 | 0% | 2024-12-31 |
| Jpmorgan Chase & Co | $227,860.00 | 2.6% | 1.59M | +72,007 | +4.75% | 2024-12-31 |
Financial Ratios
Summary
Comparison with Competitors
Analyst Recommendations
Analyst Price Targets
Screener Ideas
Dividend StocksBlue Chip StocksDefensive StocksGrowth StocksValue StocksCyclical StocksPenny StocksPrismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.